Levosimendan in cardiac amyloidosis: Unveiling promising paths
Cardiac amyloidosis (CA) is a progressive infiltrative disease primarily caused by the accumulation of misfolded, cleaved, and aggregated proteins in the extracellular space of the myocardium. CA leads to heart failure as the most frequent clinical manifestation. In recent years, research have focused on identifying and developing disease-modifying targeted therapies for CA. These efforts have resulted in improved prognosis, particularly in the setting of transthyretin CA. However, there has been less scientific interest in investigating the treatment and prompt management of patients with CA hospitalized for acute heart failure (AHF).
Source: International Journal of Cardiology - Category: Cardiology Authors: Andrea Faggiano, Stefano Carugo, Gianfranco Sinagra, Marco Merlo Source Type: research